Results 261 to 270 of about 16,064,511 (322)
Pink Polypoid Papulo‐Vesicles on Labia Majora
JEADV Clinical Practice, EarlyView.
Maria Chiara Mercuri +3 more
wiley +1 more source
Abstract Protein‐energy malnutrition is a common complication in Crohn's disease (CD). In addition to weight loss, patients may develop significant alterations in body composition, including skeletal muscle depletion, which can negatively affect clinical outcomes and quality of life.
Beatriz Gabriela da Costa +10 more
wiley +1 more source
Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? [PDF]
Saward G, Heerasing N.
europepmc +1 more source
Rethinking colitis: MrgprD puts macrophages in the driver's seat†
Abstract There is increasing evidence to suggest that dysregulated macrophages play an important role in the promotion and maintenance of inflammatory bowel disease (IBD), yet the underlying mechanisms remain unclear. A recent study published by Lv, Xia, Qiao et al in The Journal of Pathology investigated the role of Mas‐related G protein‐coupled ...
Kolja Pocha, Konstantin Bräutigam
wiley +1 more source
Macrophage SELENOP controls neutrophil homeostasis through redox stress regulation in Crohn's disease. [PDF]
Wang H +9 more
europepmc +1 more source
Fetal Intracranial Hemorrhage: What to Tell Expecting Parents?
ABSTRACT Fetal intracranial hemorrhage (ICH) is a rare but serious prenatal diagnosis, and counseling affected families remains challenging. In this narrative review, we summarize current evidence on the classification, epidemiology, etiology, diagnosis and neurodevelopmental outcomes of fetal ICH, with a primary focus on intraventricular hemorrhage ...
Shiri Shinar, Yada Kunpalin, Elka Miller
wiley +1 more source
Isolated Rectal Polypoid Lesion as the Initial Presentation of Crohn's Disease. [PDF]
Chen J, Hatfield B, Bohl JL, Tariq R.
europepmc +1 more source
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani +5 more
wiley +1 more source

